Bextra, Celebrex Class Action Lawsuit for Investors Certified

Staff Writers

Add Your Comments

A federal judge has granted class action status to an investor lawsuit brought against Pfizer over claims the company lied about the safety of Celebrex and Bextra, allegedly withholding information that the drugs caused heart problems.

On March 29, U.S. District Judge Laura Taylor Swain ruled in New York that a Celebrex and Bextra investor class action lawsuit could proceed, certifying a class that includes all individuals who purchased Pfizer stock between October 31, 2000 through October 19, 2005.

Swain indicated that the creation of a class action lawsuit will help with court efficiency and allow plaintiffs to pool their resources.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

The lawsuit was brought by investors who allege that Pfizer knowingly misrepresented information about the risk of side effects of Celebrex and Bextra causing cardiovascular problems.

Pfizer officials tried to block approval of the class action but failed. Company officials noted that the ruling does not address whether the case has merit.

Celebrex and Bextra are pain medications that were sold by Pfizer to millions of Americans.  Also known as COX-2 enzyme inhibitors, the drugs reduce pain and inflammation in the back and neck and pain from arthritis.  However, they have also been linked to increased cardiovascular risk, including heart attacks and strokes.

In 2008, Pfizer paid nearly $1 billion to settle Celebrex and Bextra lawsuits brought by plaintiffs who said they were injured by the drugs’ side effects.

Pfizer issued a Bextra recall in April 2005 after it was linked to heart attacks, strokes, blood clots and other injuries such as the Stevens-Johnson Syndrome (SJS), which is a serious and potentially fatal skin reaction. Celebrex is still on the market.

Tags: Bextra, Blood Clot, Celebrex, Class Action, Heart Attacks, Heart Disease, New York, Pfizer, Stevens-Johnson Syndrome, Stroke

More Lawsuit Stories

3 Comments

Catherine
I did not know about law suit for Vioxx Celebrex Bextra
chris
now that the class action suit has ended or the expiry past, is a person still able to file a suit against pfitzer for someone who had fallen under most of the guidelines such as purchase dates, but was not affected until 8 day’s after the class action lawsuit had closed?
Marcel
I Have chest pain all the time , I take celebrex every day without knowing it’s killing me slowly but surely. I go to the emergency rooms and they said they don’t see anything but all the time they know all my medicines that I’m takeing but not one time over all of these years of taking celebrex that they would say it’s the celebrex that you are taking that’s causeing all of my chest pains. So instead they would leave me to believe that it’s all in my mine instead of the celebrex, and they be knowing exactly what it is that could be the cause and won’t even tell you.

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Abbott-Similac-NEC-Settlement
Abbott Laboratories has agreed to pay $670 million to resolve more than 2,000 Similac NEC injury lawsuits, as the first federal NEC trial against competitor Mead Johnson gets underway.
Dupixent Lymphoma Lawsuit Alleges Atopic Dermatitis Drug Led to Mycosis Fungoides Diagnosis
A California woman’s Dupixent lymphoma lawsuit claims the manufacturers knew of the eczema drug’s cancer risks, but refused to inform doctors and patients.
MORE ABOUT: DUPIXENT LAWSUIT
FanDuel Addiction Lawsuit Alleges Targeted Advertising Caused Substantial Gambling Losses
A FanDuel addiction lawsuit claims a Pennsylvania man wagered massive amounts of money after being subjected to a tailored promotional campaign designed to exploit his gambling habits.